End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.94 CNY | +0.41% | +0.61% | -2.18% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- Revenue estimates are regularly revised downwards for the current and coming years.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.18% | 1.74B | C+ | ||
+19.98% | 43.48B | B- | ||
+20.67% | 22.65B | B+ | ||
+14.56% | 14.73B | - | ||
+44.72% | 12.04B | B | ||
-8.37% | 7.08B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+11.90% | 5.47B | B+ | ||
-2.27% | 4.81B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600572 Stock
- Ratings Zhejiang CONBA Pharmaceutical Co.,Ltd.